Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTLA-2002 phase 1/2 study in adults with hereditary angioedema
NL-OMON54405Phase 2Recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Apr 2022
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of lonvoguran in hereditary angioedema (HAE) (2 arms), sponsored by Intellia Therapeutics. Primary endpoints: Safety and tolerability, Dose-limiting toxicities and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
lonvoguran
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON54405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54405.